In this context, a key role is played by the DA D2 receptor, whose pharmacological activation reduces the cAMP levels and PKA activity, but the knowledge of the precise mechanism by which its activation reduces the effects of rotenone in mice requires a further more detailed molecular analysis in both physiological conditions and in Lrrk2-related PD. Here, LRRK2 is linked to Parkinson disease.